Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
Iwamoto T, Katagiri T, Niikura N, Miyoshi Y, Kochi M, Nogami T, Shien T, Motoki T, Taira N, Omori M, Tokuda Y, Fujiwara T, Doihara H, Gyorffy B, Matsuoka J.
Iwamoto T, et al. Among authors: omori m.
Oncotarget. 2017 Apr 18;8(16):26122-26128. doi: 10.18632/oncotarget.15385.
Oncotarget. 2017.
PMID: 28412725
Free PMC article.